<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amiodarone: Adverse effects, potential toxicities, and approach to monitoring</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amiodarone: Adverse effects, potential toxicities, and approach to monitoring</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Amiodarone: Adverse effects, potential toxicities, and approach to monitoring</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elsa-Grace Giardina, MD, MS, FACC, FACP, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rod Passman, MD, MSCE</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Link, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Zimetbaum, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> has multiple effects on myocardial depolarization and repolarization that make it an extremely effective antiarrhythmic drug. Its primary effect is to block the potassium channels, but it can also block sodium and calcium channels and the beta and alpha adrenergic receptors. (See  <a class="medical medical_review" href="/d/html/895.html" rel="external">"Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"</a>.)</p><p>Long-term use of oral <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> has been associated with a relatively high incidence of adverse effects that can range in severity from mild to potentially lethal. While long-term contemporary use of amiodarone has generally been at lower doses (200 to 300 mg/day) than were historically used, even low doses may be associated with significant adverse effects, particularly pulmonary, thyroid, cardiac, skin, and ocular toxicities. Many of these effects are due to the tissue accumulation of amiodarone with long-term oral therapy and are not seen with short-term intravenous therapy.</p><p>The major adverse effects of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, along with the approach to baseline testing and serial monitoring, will be reviewed here. The clinical uses of amiodarone, including recommendations for its use in the treatment of various arrhythmias, are discussed separately. (See  <a class="medical medical_review" href="/d/html/926.html" rel="external">"Amiodarone: Clinical uses"</a> and  <a class="medical medical_review" href="/d/html/1035.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"</a> and  <a class="medical medical_review" href="/d/html/1028.html" rel="external">"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest", section on 'Amiodarone'</a>.)</p><p class="headingAnchor" id="H345679583"><span class="h1">RATIONALE FOR MONTORING</span><span class="headingEndMark"> — </span>The long half-life of oral <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> (25 to 100 days) and the potential severity and irreversible nature of some the adverse effects make early recognition of any potential adverse effects important. As a result, baseline testing and careful monitoring of patients taking amiodarone is essential.</p><p>The need for baseline testing and monitoring depends on the route of administration and anticipated dose and duration of therapy. Many of the adverse effects associated with oral <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> are due to tissue accumulation of the drug with long-term therapy and are not seen with short-term use of intravenous amiodarone [<a href="#rid1">1</a>]. If only short term use is anticipated (eg, to prevent perioperative atrial fibrillation in patient undergoing cardiac surgery, cardioversion in a critically ill patient), no serial monitoring is typically needed, whereas patients in whom long-term use is anticipated should undergo appropriate baseline testing and serial monitoring.</p><p>Intravenous (IV) <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> is generally used in the management of life-threatening ventricular arrhythmias or in critically ill patients with atrial fibrillation. Patients receiving IV amiodarone are generally on continuous electrocardiographic (ECG) monitoring with frequent assessment of vital signs. Such monitoring is appropriate in all patients due to the potential for hypotension and arrhythmias. If only short-term IV use is anticipated without a plan for long-term oral therapy, no baseline testing is required. However, for patients in whom a transition to long-term oral amiodarone is anticipated, the usual baseline laboratories should be obtained  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/926.html" rel="external">"Amiodarone: Clinical uses"</a>.)</p><p class="headingAnchor" id="H3149378134"><span class="h1">ADVERSE EFFECTS OF ORAL AMIODARONE</span></p><p class="headingAnchor" id="H3"><span class="h2">Adverse pulmonary effects</span><span class="headingEndMark"> — </span>Pulmonary toxicity is one of the more common adverse effects of long-term <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> and is responsible for most of the rare deaths associated with amiodarone therapy  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>). While this issue is discussed in detail separately, a brief overview will be presented here, along with recommendations for baseline testing and serial monitoring. (See  <a class="medical medical_review" href="/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity"</a>.)</p><p class="headingAnchor" id="H3348732475"><span class="h3">Clinical presentation of pulmonary toxicity</span><span class="headingEndMark"> — </span>Initial reports in which patients were usually treated with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> doses ≥400 mg/day noted a 5 to 15 percent incidence of pulmonary toxicity [<a href="#rid2">2-4</a>]. However, the incidence is less than 2 percent with lower maintenance doses used in contemporary practice [<a href="#rid3">3,5-7</a>].</p><p>Pulmonary toxicity is more frequent in those with advanced age or pre-existing lung disease [<a href="#rid8">8</a>], but generally correlates more closely with the total cumulative dose than with serum drug levels [<a href="#rid6">6,8,9</a>]. As a result, pulmonary toxicity usually occurs several months to as late as several years after the initiation of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy [<a href="#rid6">6</a>]. However, there are anecdotal cases of severe pulmonary toxicity developing within two to three weeks of therapy with low cumulative doses [<a href="#rid10">10</a>].</p><p>Chronic interstitial pneumonitis is the most common pulmonary toxicity associated with long-term <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy. A nonproductive cough and dyspnea are present in 50 of 75 percent of affected individuals at presentation. Pleuritic pain, weight loss, fever (33 to 50 percent of cases), and malaise can also occur. The physical examination often reveals bilateral inspiratory crackles, while clubbing is not seen. (See  <a class="medical medical_review" href="/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity", section on 'Clinical manifestations'</a>.)</p><p>Several other pulmonary toxicities, including eosinophilic pneumonia, organizing pneumonia, acute respiratory distress syndrome, alveolar hemorrhage, and pulmonary nodules, have been reported less frequently. (See  <a class="medical medical_review" href="/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity"</a>.)</p><p class="headingAnchor" id="H1536237402"><span class="h3">Baseline pulmonary testing</span><span class="headingEndMark"> — </span>Recommended baseline testing for patients who are starting long-term therapy with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> consists of only a chest radiograph. There are differing opinions, and no consensus, of obtaining formal pulmonary function tests (PFTs) with assessment of diffusion capacity (ie, diffusion capacity of the lungs for carbon monoxide [DLCO]) as baseline testing in all patients. Some experts obtain baseline PFTs with DLCO prior to starting amiodarone, particularly among patients with underlying lung disease, while other experts rarely or never obtain baseline PFTs  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2408022609"><span class="h3">Serial pulmonary monitoring and symptomatic follow up</span><span class="headingEndMark"> — </span>We perform a yearly chest radiograph for asymptomatic patients as long as they are taking <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>; however, we do not perform serial PFTs for asymptomatic patients, as PFTs are not helpful for predicting pulmonary toxicity. However, any patient who develops dyspnea or other symptoms suggestive of possible pulmonary toxicity should have both a chest radiograph and formal PFTs (including DLCO) and, as indicated by abnormal PFT findings, chest computed tomography. (See  <a class="medical medical_review" href="/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity", section on 'Evaluation'</a>.)</p><p>Although DLCO is often decreased in patients with pulmonary toxicity, there is usually no premonitory change in DLCO among asymptomatic patients in whom symptomatic disease subsequently develops. As a result, the DLCO is <strong>not</strong> useful as a predictive index [<a href="#rid11">11,12</a>]. In one report, for example, most asymptomatic patients with a fall in DLCO of more than 20 percent did not develop pulmonary toxicity over the next year despite continued <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H2302793596"><span class="h3">Treatment of pulmonary toxicity</span><span class="headingEndMark"> — </span>The treatment of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> pulmonary toxicity typically involves discontinuing the medication and systemic glucocorticoids. Details regarding treatment are presented separately. (See  <a class="medical medical_review" href="/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Adverse thyroid effects</span><span class="headingEndMark"> — </span>Thyroid dysfunction (including both hypothyroidism and hyperthyroidism) is considered the most frequent complication of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> treatment  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>). While this issue is discussed in detail separately, a brief overview will be presented here along with recommendations for baseline testing and serial monitoring. (See  <a class="medical medical_review" href="/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction"</a>.)</p><p class="headingAnchor" id="H1360555504"><span class="h3">Clinical presentation of thyroid toxicity</span><span class="headingEndMark"> — </span>Although initial reports using higher doses noted hyperthyroidism or hypothyroidism in up to 20 percent of patients, the risk is lower (approximately 3 to 4 percent) when lower doses are used [<a href="#rid5">5</a>]. In a large Danish cohort (43,724 patients), the cumulative incidence of thyroid dysfunction following <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> in previously untreated patients was 5 percent in patients with heart failure and 4 percent in those without heart failure [<a href="#rid13">13</a>]. In this nationwide study, approximately 5 percent of patients who initiated treatment with amiodarone had thyroid dysfunction at one-year follow-up. In addition, a dose-response relationship was observed between the accumulated dose of amiodarone within the first year and the five-year incidence of thyroid dysfunction. Patients with heart failure who initiated amiodarone received higher accumulated doses of amiodarone and displayed significantly higher associated rates of thyroid dysfunction.</p><p>Underlying thyroid status and iodine intake appear to influence the incidence and type of thyroid dysfunction seen with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy [<a href="#rid14">14</a>]. The clinical manifestations of hypothyroidism (eg, fatigue, cold intolerance, constipation, weight gain, coarse hair and skin, etc) and hyperthyroidism (eg, restlessness, unexplained weight loss, low-grade fever, hypertension, tachycardia, etc) are similar to thyroid disease from any etiology, although the intrinsic beta blocking properties of amiodarone may mask some of the hyperthyroid symptoms. (See  <a class="medical medical_review" href="/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism"</a> and  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p class="headingAnchor" id="H1170756765"><span class="h3">Baseline thyroid testing and serial monitoring</span><span class="headingEndMark"> — </span>Patients should undergo thyroid function testing prior to initiating treatment with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, again within three to four months of initiating amiodarone, and every 12 months during chronic amiodarone therapy  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>). The onset of amiodarone-induced hypothyroidism two years after initiating therapy is rare; thus, the drug might be continued according to underlying indication with low concern of hypothyroidism induction. However, hyperthyroidism resulting from amiodarone can still be possible, and appropriate assessments are required individually. Typically, a thyroid-stimulating hormone (TSH) level can be ordered and, if normal, testing is complete. Follow-up for an abnormal TSH varies depending upon the direction of the TSH abnormality:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated TSH (suggesting hypothyroidism) – free T4 level</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased TSH (suggesting hyperthyroidism) – free T4 level and total T3 level</p><p></p><p>Consultation with an endocrinologist is often warranted to determine the optimal course of action following abnormal thyroid function testing.</p><p class="headingAnchor" id="H2686082258"><span class="h3">Treatment of thyroid dysfunction</span><span class="headingEndMark"> — </span>The treatment of amiodarone-induced thyroid dysfunction is reviewed briefly here but discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with hypothyroidism can usually be treated with thyroid hormone replacement and maintained on <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with amiodarone-induced hyperthyroidism should be evaluated by, and treated in conjunction with, an endocrinologist. Such patients may benefit from discontinuing <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> if no life-threatening arrhythmias are present and other antiarrhythmic options are available.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Adverse cardiac effects</span></p><p class="headingAnchor" id="H7"><span class="h3">Clinical presentation of cardiac toxicity</span><span class="headingEndMark"> — </span>Multiple cardiac effects can be seen in patients taking chronic <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>). Sinus bradycardia is an expected result from amiodarone treatment, but excessive bradycardia or AV block often represents toxicity. Amiodarone does generally lead to prolongation of the QT interval, but this is rarely proarrhythmic. Finally, amiodarone can alter the defibrillation thresholds for patients with implantable cardioverter-defibrillators (ICDs).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bradycardia and AV block</strong> – <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> can directly cause both sinus bradycardia and AV nodal block, due primarily to its calcium channel blocking activity. The overall incidence of bradycardic events has been approximately 3 to 5 percent [<a href="#rid15">15</a>]. In the meta-analysis of chronic low-dose amiodarone (mean 150 to 330 mg/day), the incidence of bradycardic events was significantly greater than with placebo (3.3 versus 1.4 percent; odds ratio [OR] 2.2, 95% CI 1.1-4.3) [<a href="#rid5">5</a>]. Typically sinus bradycardia results in few or no symptoms, but patients with second or third degree AV block are usually symptomatic with one or more of lightheadedness, presyncope, syncope, dyspnea, or fatigue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>QT prolongation and proarrhythmia</strong> – As with most antiarrhythmic drugs, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> can result in prolongation of the QT interval [<a href="#rid16">16</a>]. However, the incidence of proarrhythmia is lower with amiodarone than other class III drugs (eg, <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="8548" href="/d/drug information/8548.html" rel="external">ibutilide</a>, and <a class="drug drug_general" data-topicid="8904" href="/d/drug information/8904.html" rel="external">dofetilide</a>), with an incidence of torsades de pointes ≤1 percent [<a href="#rid7">7</a>]; the exact electrophysiologic mechanisms responsible for the low proarrhythmic activity of amiodarone remain incompletely understood [<a href="#rid4">4,5,17-19</a>]. In the meta-analysis of low-dose therapy, there were no cases of torsades de pointes in the 738 patients treated with amiodarone for at least one year [<a href="#rid5">5</a>]. Several factors contribute to the rarity of torsades de pointes with amiodarone: lack of reverse use dependence; concurrent blockade of the L-type calcium channels; and less heterogeneity of ventricular repolarization (less QT dispersion). Torsades de pointes associated with amiodarone therapy is more likely to occur in women due to slightly longer average baseline QT intervals in women, and is much more likely to occur with other factors that can cause QT prolongation such as hypokalemia, hypomagnesemia, and concomitant use of other drugs that prolong the QT interval [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Risk factors for drug-induced long QT syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interaction with ICDs</strong> – <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> may have important interactions with ICDs. It may slow the ventricular tachycardia rate, possibly precluding its recognition by the device by decreasing the rate of the VT below the VT detection zone, and its major metabolite desethylamiodarone increases the defibrillation threshold in a dose-dependent fashion; this effect is seen with monophasic and biphasic waveforms [<a href="#rid21">21-24</a>]. If amiodarone is initiated in a patient with known elevated defibrillation thresholds (DFTs) or risk factors for elevated DFTs, a noninvasive ICD evaluation should be performed to test for adverse drug-device interactions once loading is complete [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H3316045840"><span class="h3">Baseline cardiac testing and serial monitoring</span><span class="headingEndMark"> — </span>All patients should have an ECG prior to starting <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy and annually for the duration of therapy, or more frequently in response to a change in symptoms  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>). Patients with an ICD are followed in accordance with standard practice for device monitoring. (See  <a class="medical medical_review" href="/d/html/1015.html" rel="external">"Cardiac implantable electronic devices: Patient follow-up"</a>.)</p><p class="headingAnchor" id="H2497293816"><span class="h3">Management of adverse cardiac effects</span><span class="headingEndMark"> — </span>The management of adverse cardiac effects related to <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> varies depending upon the adverse effect and may require dose reduction or discontinuation of amiodarone. Despite dose modification or cessation of amiodarone, cardiac adverse effects may persist due to the drug’s long half-life. If the effects are clinically significant, then urgent treatment (eg, pacing) may be required as the amiodarone tissue concentrations decrease.</p><p class="bulletIndent1"><span class="glyph">●</span>Sinus bradycardia – If sinus bradycardia occurs during therapy, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> and other drugs with negative chronotropic effects should be discontinued or dose-reduced, if possible. If amiodarone therapy is necessary and sinus bradycardia persists after medications have been modified, placement of a permanent pacemaker capable of atrial pacing may be required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High grade AV block – If high grade (second or third degree) AV block develops during therapy, options include reducing the dose of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> or other medications that cause AV block. If AV block does not resolve despite medication changes, placement of a permanent pacemaker may be necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>QT prolongation – While <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> prolongs the QT interval, the authors and editors of this topic agree that amiodarone-induced arrythmias are rare and that amiodarone is generally safe despite mild prolongation of the QT interval. When the QT interval is above 550 milliseconds, we avoid concomitant use of medications that interact with amiodarone metabolism or intrinsically prolong the QT interval [<a href="#rid25">25</a>]. A detailed discussion of amiodarone-induced arrhythmias can be found separately. (See  <a class="medical medical_review" href="/d/html/926.html" rel="external">"Amiodarone: Clinical uses", section on 'Electrophysiologic properties'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased ICD defibrillation threshold – If ongoing treatment with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> is required and results in an unacceptably high defibrillation threshold, options include using a high-output device, reprogramming the shock waveform (eg, duration, amplitude), repositioning the lead, or adding a subcutaneous array.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Adverse hepatic effects</span></p><p class="headingAnchor" id="H1682470257"><span class="h3">Clinical presentation of hepatotoxicity</span><span class="headingEndMark"> — </span>A transient rise in serum aminotransferase concentrations occurs in approximately 25 percent (range 15 to 50 percent) of patients soon after <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> is begun; most patients are asymptomatic with this [<a href="#rid26">26</a>]. Symptomatic hepatitis occurs in less than 3 percent of patients; potential complications include cirrhosis and hepatic failure [<a href="#rid26">26,27</a>]. Jaundice is an unusual adverse effect that may be due to intrahepatic cholestasis [<a href="#rid28">28,29</a>]. Serum bilirubin concentrations may first increase or continue to increase for a period of time after the drug is discontinued [<a href="#rid28">28,29</a>]. These findings are consistent with the long half-life of amiodarone (25 to 100 days). Both direct hepatotoxicity and metabolic idiosyncrasy are thought to contribute to amiodarone-induced hepatic injury [<a href="#rid26">26,30</a>].</p><p class="headingAnchor" id="H3703337586"><span class="h3">Baseline hepatic function assessment and serial monitoring</span><span class="headingEndMark"> — </span>Prior to beginning chronic <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy, baseline testing  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>) should include serum transaminase levels (ALT and AST). These tests should be repeated every 12 months for the duration of therapy for following the development of signs or symptoms suggesting liver disease [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H359561297"><span class="h3">Treatment of hepatic toxicity</span><span class="headingEndMark"> — </span>Although the relation of hepatotoxicity to cumulative dose and duration of therapy is uncertain, it is likely that cumulative dose correlates with overall toxicity and, therefore, that maintenance doses should be kept as low as possible. In the meta-analysis of chronic low-dose <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> (mean 150 to 330 mg/day), the incidence of hepatotoxicity was low and not significantly different from placebo (1.2 versus 0.8 percent; OR 1.2, 95% CI 0.4-3.3) [<a href="#rid5">5</a>].</p><p><a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> should be discontinued in most cases if there is more than a twofold elevation in serum transaminase levels from baseline, or in patients diagnosed with hepatitis [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Adverse ocular effects</span><span class="headingEndMark"> — </span>Corneal microdeposits are an expected finding in patients on chronic oral <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, typically with minimal to no impact on vision. In contrast, rare cases of optic neuropathy have been reported, with the potential to progress to blindness if undiagnosed and untreated. All patients should have a baseline eye examination prior to (or shortly after) initiating chronic oral amiodarone therapy  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>). Annual eye examinations are recommended but not required if patients remain asymptomatic while taking amiodarone; however, patients with visual symptoms while on amiodarone should be promptly referred for a repeat eye examination.</p><p class="headingAnchor" id="H13"><span class="h3">Corneal microdeposits</span><span class="headingEndMark"> — </span>Corneal microdeposits occur in most patients receiving long-term <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy, while some patients also develop lenticular opacities [<a href="#rid31">31-33</a>]. The corneal microdeposits are caused by the secretion of amiodarone by the lacrimal gland with accumulation on the corneal surface. They are identifiable on ophthalmologic examination as a brownish whorl at the juncture of the lower one-third and upper two-thirds of the cornea and have been described as resembling a cat's whiskers [<a href="#rid31">31</a>]. The formation of microdeposits is dose-dependent; the changes are reversible within seven months after amiodarone is discontinued [<a href="#rid32">32</a>].</p><p>Corneal microdeposits do not reduce visual acuity. However, ocular symptoms occur in a small number of patients [<a href="#rid31">31,32</a>]. These include halo vision (colored rings around lights), particularly at night, photophobia, and blurred vision. The incidence has been reported as 1.5 percent in a meta-analysis of trials of chronic low-dose <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> (mean dose 150 to 330 mg/day), compared with 0.1 percent seen with placebo (OR 3.4, 95% CI 1.2-9.6) [<a href="#rid5">5,32</a>].</p><p>The presence of microdeposits is not considered a contraindication to continued <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy, since visual acuity is rarely affected [<a href="#rid31">31,32</a>]. In any patient with visual symptoms who is taking amiodarone, other common factors (a change in refractive correction, progression of age-related cataract, or increased intraocular pressure) should be considered before attributing the change to the drug.</p><p class="headingAnchor" id="H14"><span class="h3">Optic neuropathy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> has been reported to cause optic nerve injury, with unilateral or bilateral visual loss that can rarely progress to permanent blindness [<a href="#rid31">31,34,35</a>]. Whether the prevalence of this adverse effect increases with time is unclear, although some survey data have reported that the prevalence may increase over time [<a href="#rid31">31</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a report of 296 cases of optic neuropathy identified through the US Food and Drug Administration adverse event reporting system, the mean duration of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> treatment prior to visual loss was nine months (ranging from 1 to 84 months); nearly one-third of cases were asymptomatic [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a Taiwanese nationwide cohort study, which included 6175 patients who started treatment with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> between 2005 and 2009 (along with 24,700 matched controls) and were followed for an average of 1.9 years, significantly more amiodarone-treated patients developed optic neuropathy (17 [0.3 percent] versus 30 [0.1 percent] of controls; adjusted hazard ratio 2.1, 95% CI 1.1-3.9) [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a post hoc report from the SCD-HeFT trial in which patients were randomized to <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> (n = 837) or placebo (n = 832), there were no reported cases of bilateral vision loss over a relatively short duration of follow-up (median 45.5 months) [<a href="#rid37">37</a>].</p><p></p><p>Additional long-term data are needed to clarify the incidence of optic neuropathy and potential causation from <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>. However, given the potential for permanent visual loss, immediate cessation of amiodarone or dose reduction is recommended for patients who develop optic neuropathy unless the arrhythmia is life-threatening and an alternative antiarrhythmic drug is not available [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Other</span><span class="headingEndMark"> — </span>Long-term <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy has several other potential toxicities.</p><p class="headingAnchor" id="H16"><span class="h3">Adverse skin reactions</span><span class="headingEndMark"> — </span>Various skin reactions, previously more common when higher doses of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> were used, were reported in 2.3 percent of patients (compared with 0.7 percent in placebo recipients; OR 2.5, 95% CI 1.1-6.2) in the meta-analysis of chronic low-dose amiodarone therapy (mean dose 150 to 300 mg/day) [<a href="#rid5">5</a>]. Types of skin reactions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Photosensitivity, which can be treated with avoidance of sun exposure and the use of sunblock.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bluish-slate gray discoloration of the skin (so-called "blue man syndrome"), which is usually most prominent on the face  (<a class="graphic graphic_picture graphicRef70419" href="/d/graphic/70419.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other reported adverse effects include hyperpigmentation, pseudoporphyria, and bullous dermatitis [<a href="#rid38">38</a>].</p><p></p><p>The bluish-slate gray discoloration of the skin occurs in 1 to 3 percent of patients on chronic <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy and appears to be due to the deposition of lipofuscin in the dermis [<a href="#rid39">39-41</a>]. There may be a tissue threshold for amiodarone in individual patients above which skin discoloration appears and below which it fades [<a href="#rid42">42</a>]. Thus, patients disturbed by skin pigmentation who are taking large doses (more than 400 mg/day) may notice improvement in skin discoloration by reducing the dose.</p><p>There is no specific therapy for the skin discoloration, but affected patients are advised to avoid sun exposure. Complete resolution after cessation of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy may take one year or more [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Adverse gastrointestinal effects</span><span class="headingEndMark"> — </span>Gastrointestinal adverse effects associated with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy, which include nausea, vomiting, anorexia, diarrhea, and constipation, occur mostly during the initial loading phase of therapy [<a href="#rid5">5,15</a>]. While previously reported in up to 30 percent of patients, findings from the meta-analysis of chronic low-dose amiodarone therapy suggest that gastrointestinal adverse effects are not significantly more frequent than with placebo (4.2 versus 3.3 percent) [<a href="#rid5">5</a>]. Taking the medication with food or reducing the dose when possible can reduce GI side effects.</p><p class="headingAnchor" id="H18"><span class="h3">Adverse neurologic function</span><span class="headingEndMark"> — </span>Neurologic toxicity associated with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy may take many forms, including tremor, ataxia, peripheral neuropathy with paresthesias, and sleep disturbances; similar to other toxicities, these appear to be dose-related in patients requiring higher doses [<a href="#rid5">5,15,44</a>]. In the meta-analysis of chronic low-dose amiodarone therapy (mean dose 150 to 330 mg/day), neurologic side effects were much less common than what was reported in early studies that utilized higher doses of amiodarone, but still significantly more frequent than with placebo (4.6 versus 1.9 percent; OR 2.0, 95% CI 1.1-3.7) [<a href="#rid5">5</a>]. We recommend stopping amiodarone to see if symptoms resolve.</p><p class="headingAnchor" id="H22"><span class="h2">Adverse drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> is highly bound to plasma proteins (&gt;96 percent) and can alter the plasma concentration of other highly bound drugs. Additionally, amiodarone can interfere with the hepatic metabolism of several antiarrhythmic drugs (such as <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>, and <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>), possibly leading to supratherapeutic plasma concentrations if the dose is not reduced. These interactions are particularly worrisome because they may persist for as long as three months after the cessation of therapy due to the long elimination half-life of amiodarone (25 to 100 days). See the <a class="external" href="/drug-interactions">drug interactions program</a> for additional information including specific dose adjustments or limits and management suggestions.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">Digoxin</a> – <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> can interfere with the metabolism of digoxin, raising the plasma digoxin concentration and potentially leading to digoxin toxicity. The dose of digoxin should be empirically reduced by 50 percent at the time of amiodarone initiation or the need for digoxin reevaluated altogether. Digoxin levels should be measured within three days after amiodarone initiation. (See  <a class="medical medical_review" href="/d/html/1051.html" rel="external">"Treatment with digoxin: Initial dosing, monitoring, and dose modification", section on 'Dose adjustment with concomitant medications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> – <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> can also interfere with the metabolism of warfarin, which often necessitates approximately a 25 percent reduction in warfarin dose to prevent an elevation in the international normalized ratio (INR) and potential bleeding complications [<a href="#rid45">45,46</a>]. In a retrospective cohort study of 754 patients treated with chronic warfarin therapy in whom amiodarone was started, the average INR increased from 2.6 to 3.1, with an average reduction in warfarin dose of 24.6 percent [<a href="#rid46">46</a>]. The INR level should be checked more frequently in the one to two weeks after amiodarone is initiated.</p><p></p><p class="bulletIndent1">The interaction between <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> and <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is further complicated by the potential effects of amiodarone on thyroid function. The effect of warfarin is potentiated by thyrotoxicosis and attenuated in hypothyroidism [<a href="#rid47">47</a>]. Thyroid function should be reassessed in any patient on a stable warfarin and amiodarone regimen if the INR changes unexpectedly. (See <a class="local">'Adverse thyroid effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct oral anticoagulants (DOACs)</strong> – There are limited data concerning drug-drug interactions of DOACs and <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>. It is currently recommended that clinicians consider alternative combinations or adjust the DOAC dose to minimize the risk of bleeding [<a href="#rid48">48</a>]. A retrospective, population-based, nested case-control study found a significant association between major bleeding and current use of amiodarone among older patients with atrial fibrillation on a DOAC (ie, there was 53 percent increased odds of major bleeding with current use of amiodarone) [<a href="#rid49">49</a>]. Accordingly, caution should be used in the coprescription of amiodarone and DOACs, and the risk of major bleeding should be considered in determining the risks of a drug-drug interaction between amiodarone and DOACs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">Simvastatin</a> – <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> alters the metabolism of simvastatin, resulting in a significantly higher risk of rhabdomyolysis when both drugs are used concurrently. If amiodarone and simvastatin are required in the same patient, the dose of simvastatin should be <strong>no higher than</strong> 20 mg daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other drugs</strong> – <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> can increase the plasma concentration of other medications including <a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and other hepatically metabolized drugs including some antidepressants.</p><p></p><p class="headingAnchor" id="H2158832"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for monitoring </strong>– The long half-life of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> (25 to 100 days) and the potential severity of some of the adverse effects make early recognition important. Thus, baseline testing and careful monitoring of patients taking amiodarone is essential  (<a class="graphic graphic_table graphicRef126072" href="/d/graphic/126072.html" rel="external">table 1</a>). (See <a class="local">'Rationale for montoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse pulmonary effects</strong> – Pulmonary toxicity is a common adverse effect of long-term <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> and is rarely fatal. Pulmonary toxicity generally correlates more closely with the total cumulative dose than with serum drug levels. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several different types of adverse pulmonary effects may occur, including chronic interstitial pneumonitis, the most common. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms include a nonproductive cough and dyspnea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical examination often reveals bilateral inspiratory crackles. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> pulmonary toxicity is one of exclusion. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment consists primarily of stopping <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, with corticosteroid therapy administered in patients with symptomatic pulmonary toxicity. (See <a class="local">'Adverse pulmonary effects'</a> above and  <a class="medical medical_review" href="/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid dysfunction </strong>– This includes both hypothyroidism and hyperthyroidism and is another common complication of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy, occurring in approximately 3 to 4 percent of patients when lower doses (&lt;400 mg/day) are used. Underlying thyroid status and iodine intake appear to influence the incidence and type of thyroid dysfunction seen with amiodarone therapy. (See <a class="local">'Adverse thyroid effects'</a> above and  <a class="medical medical_review" href="/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse cardiac effects </strong>– These can include excessive sinus bradycardia, AV block, and QT interval prolongation (usually not arrhythmogenic). Finally, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> can alter the defibrillation thresholds for patients with an implantable cardioverter-defibrillators (ICDs). Management varies depending upon the adverse effect. (See <a class="local">'Adverse cardiac effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse hepatic effects </strong>– Symptomatic hepatitis occurs in less than 3 percent of patients on <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, and potential complications such as cirrhosis and hepatic failure occur very infrequently. However, a transient asymptomatic rise in serum aminotransferase concentrations occurs in approximately 25 percent of patients soon after beginning amiodarone. Although the relation of hepatotoxicity to cumulative dose and duration of therapy is uncertain, it is likely that cumulative dose correlates with overall toxicity. While patients are usually asymptomatic, the drug should be discontinued if there is more than a twofold elevation in serum aminotransferases. (See <a class="local">'Adverse hepatic effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse ocular effects </strong>– Corneal microdeposits occur in most patients receiving long-term <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> therapy, while some patients also develop lenticular opacities. While corneal microdeposits do not reduce visual acuity, ocular symptoms may occur, including halo vision (colored rings around lights), photophobia, and blurred vision. The presence of microdeposits is not considered a contraindication to continued amiodarone therapy since visual acuity is rarely affected. (See <a class="local">'Corneal microdeposits'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse drug interactions </strong>– <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">Amiodarone</a> is highly bound to plasma proteins (&gt;96 percent) and can alter the plasma concentration of other highly bound drugs. Additionally, amiodarone can interfere with the hepatic metabolism of several antiarrhythmic drugs (such as <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>, and <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>), possibly leading to supratherapeutic plasma concentrations if the dose is not reduced. (See <a class="local">'Adverse drug interactions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997; 127:294.</a></li><li><a class="nounderline abstract_t">Mason JW. Amiodarone. N Engl J Med 1987; 316:455.</a></li><li><a class="nounderline abstract_t">Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82:51.</a></li><li><a class="nounderline abstract_t">Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007; 356:935.</a></li><li><a class="nounderline abstract_t">Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.</a></li><li><a class="nounderline abstract_t">Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest 1988; 93:1067.</a></li><li><a class="nounderline abstract_t">Kim D, Yang PS, You SC, et al. Age and Outcomes of Early Rhythm Control in Patients With Atrial Fibrillation: Nationwide Cohort Study. JACC Clin Electrophysiol 2022; 8:619.</a></li><li><a class="nounderline abstract_t">Kwok WC, Ma TF, Chan JWM, et al. A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity. BMC Pulm Med 2022; 22:128.</a></li><li><a class="nounderline abstract_t">Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J 2009; 16:43.</a></li><li><a class="nounderline abstract_t">Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 2002; 89:896.</a></li><li><a class="nounderline abstract_t">Mason JW. Prediction of amiodarone-induced pulmonary toxicity. Am J Med 1989; 86:2.</a></li><li><a class="nounderline abstract_t">Gleadhill IC, Wise RA, Schonfeld SA, et al. Serial lung function testing in patients treated with amiodarone: a prospective study. Am J Med 1989; 86:4.</a></li><li><a class="nounderline abstract_t">Ali SA, Ersbøll M, Vinding NE, et al. Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study. Europace 2023; 25:291.</a></li><li><a class="nounderline abstract_t">Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101:28.</a></li><li><a class="nounderline abstract_t">Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741.</a></li><li><a class="nounderline abstract_t">Malfatto G, Zaza A, Facchini M. Different effects of antiarrhythmic drugs on the rate-dependency of QT interval: a study with amiodarone and flecainide. J Cardiovasc Pharmacol 2007; 50:535.</a></li><li><a class="nounderline abstract_t">Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994; 121:529.</a></li><li><a class="nounderline abstract_t">Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995; 6:920.</a></li><li><a class="nounderline abstract_t">van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001; 104:2722.</a></li><li><a class="nounderline abstract_t">Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590.</a></li><li><a class="nounderline abstract_t">Goldschlager N, Epstein A, Friedman P, et al. Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: a practical guide to patient treatment. Arch Intern Med 2001; 161:649.</a></li><li><a class="nounderline abstract_t">Zhou L, Chen BP, Kluger J, et al. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998; 31:1672.</a></li><li><a class="nounderline abstract_t">Pelosi F Jr, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000; 11:736.</a></li><li><a class="nounderline abstract_t">Nielsen TD, Hamdan MH, Kowal RC, et al. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. Am J Cardiol 2001; 88:446.</a></li><li><a class="nounderline abstract_t">Brown MA, Smith WM, Lubbe WF, Norris RM. Amiodarone-induced torsades de pointes. Eur Heart J 1986; 7:234.</a></li><li><a class="nounderline abstract_t">Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9:679.</a></li><li><a class="nounderline abstract_t">Richer M, Robert S. Fatal hepatotoxicity following oral administration of amiodarone. Ann Pharmacother 1995; 29:582.</a></li><li><a class="nounderline abstract_t">Chang CC, Petrelli M, Tomashefski JF Jr, McCullough AJ. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med 1999; 123:251.</a></li><li><a class="nounderline abstract_t">Macarri G, Feliciangeli G, Berdini V, et al. Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Ital J Gastroenterol 1995; 27:436.</a></li><li><a class="nounderline abstract_t">Somani P, Bandyopadhyay S, Klaunig JE, Gross SA. Amiodarone- and desethylamiodarone-induced myelinoid inclusion bodies and toxicity in cultured rat hepatocytes. Hepatology 1990; 11:81.</a></li><li><a class="nounderline abstract_t">Mäntyjärvi M, Tuppurainen K, Ikäheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998; 42:360.</a></li><li><a class="nounderline abstract_t">Ingram DV. Ocular effects in long-term amiodarone therapy. Am Heart J 1983; 106:902.</a></li><li><a class="nounderline abstract_t">Flach AJ, Dolan BJ. Progression of amiodarone induced cataracts. Doc Ophthalmol 1993; 83:323.</a></li><li><a class="nounderline abstract_t">Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999; 127:610.</a></li><li><a class="nounderline abstract_t">Cheng HC, Yeh HJ, Huang N, et al. Amiodarone-Associated Optic Neuropathy: A Nationwide Study. Ophthalmology 2015; 122:2553.</a></li><li><a class="nounderline abstract_t">Passman RS, Bennett CL, Purpura JM, et al. Amiodarone-associated optic neuropathy: a critical review. Am J Med 2012; 125:447.</a></li><li><a class="nounderline abstract_t">Mindel JS, Anderson J, Hellkamp A, et al. Absence of bilateral vision loss from amiodarone: a randomized trial. Am Heart J 2007; 153:837.</a></li><li><a class="nounderline abstract_t">Jaworski K, Walecka I, Rudnicka L, et al. Cutaneous adverse reactions of amiodarone. Med Sci Monit 2014; 20:2369.</a></li><li><a class="nounderline abstract_t">Enseleit F, Wyss CA, Duru F, et al. Images in cardiovascular medicine. The blue man: amiodarone-induced skin discoloration. Circulation 2006; 113:e63.</a></li><li><a class="nounderline abstract_t">Alinovi A, Reverberi C, Melissari M, Gabrielli M. Cutaneous hyperpigmentation induced by amiodarone hydrochloride. J Am Acad Dermatol 1985; 12:563.</a></li><li><a class="nounderline abstract_t">Delage C, Lagacé R, Huard J. Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J 1975; 112:1205.</a></li><li><a class="nounderline abstract_t">Kounis NG, Frangides C, Papadaki PJ, et al. Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation. Clin Cardiol 1996; 19:592.</a></li><li><a class="nounderline abstract_t">Blackshear JL, Randle HW. Reversibility of blue-gray cutaneous discoloration from amiodarone. Mayo Clin Proc 1991; 66:721.</a></li><li><a class="nounderline abstract_t">Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009; 66:865.</a></li><li><a class="nounderline abstract_t">Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 2002; 121:19.</a></li><li><a class="nounderline abstract_t">Holm J, Lindh JD, Andersson ML, Mannheimer B. The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. J Thromb Haemost 2017; 15:446.</a></li><li><a class="nounderline abstract_t">Kurnik D, Loebstein R, Farfel Z, et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83:107.</a></li><li><a class="nounderline abstract_t">Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39:1330.</a></li><li><a class="nounderline abstract_t">Shurrab M, Jackevicius CA, Austin PC, et al. Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation. Am J Cardiol 2023; 186:58.</a></li></ol></div><div id="topicVersionRevision">Topic 931 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9265430" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The role of intravenous amiodarone in the management of cardiac arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3543680" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2364524" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical features of amiodarone-induced pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329700" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Amiodarone for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9283542" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adverse effects of low dose amiodarone: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3282816" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35589174" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Age and Outcomes of Early Rhythm Control in Patients With Atrial Fibrillation: Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35382826" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19399307" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Amiodarone pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11909587" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2910091" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prediction of amiodarone-induced pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2910095" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Serial lung function testing in patients treated with amiodarone: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36504263" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6428291" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10871966" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18030063" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Different effects of antiarrhythmic drugs on the rate-dependency of QT interval: a study with amiodarone and flecainide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8067651" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8548113" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11723026" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8230644" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231696" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: a practical guide to patient treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626850" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10921789" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of chronic amiodarone therapy on defibrillation energy requirements in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11545776" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3709557" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Amiodarone-induced torsades de pointes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2785079" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7663029" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fatal hepatotoxicity following oral administration of amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086516" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8775470" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2153095" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Amiodarone- and desethylamiodarone-induced myelinoid inclusion bodies and toxicity in cultured rat hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9493278" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ocular side effects of amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6613837" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ocular effects in long-term amiodarone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8223102" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Progression of amiodarone induced cataracts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334361" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Features of amiodarone-induced optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26391464" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Amiodarone-Associated Optic Neuropathy: A Nationwide Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385784" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Amiodarone-associated optic neuropathy: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452162" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Absence of bilateral vision loss from amiodarone: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25413691" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cutaneous adverse reactions of amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461825" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Images in cardiovascular medicine. The blue man: amiodarone-induced skin discoloration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3989014" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cutaneous hyperpigmentation induced by amiodarone hydrochloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/47784" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8818442" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2072759" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Reversibility of blue-gray cutaneous discoloration from amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19597088" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Frequency, characteristics, and risk factors for amiodarone neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796427" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28058824" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028964" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562325" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36343447" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
